SCHEMBL7186476

SCHEMBL7186476

Cc1ccc2cc(Br)cc(Br)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.52
PRNP P04156 3/20 0.52
LMNA P02545 2/20 0.52
HTT P42858 2/20 0.52
HPGD P15428 1/20 0.52
NOD2 Q9HC29 1/20 0.52
RAB9A P51151 3/20 0.50
CCR1 P32246 2/20 0.50
CCR5 P51681 2/20 0.50
RXFP1 Q9HBX9 4/20 0.49
MAPT P10636 3/20 0.49
ALDH1A1 P00352 1/20 0.49
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
NQO2 P16083 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974625 0.82 CCR1 (0.48) NPSR1PRNPLMNAHTTHPGD
SCHEMBL11624013 0.80 CCR1 (0.46) NPSR1PRNPLMNAHTTHPGD
SCHEMBL3711580 0.80 METAP2 (0.53) NPSR1PRNPLMNAHTTHPGD
SCHEMBL2119502 0.80 CCR1 (0.46) NPSR1PRNPLMNAHTTHPGD
SCHEMBL3332400 0.77 CCR1 (0.43) LMNAHTTRAB9ACCR1CCR5
SCHEMBL29923496 0.77 RAB9A (0.43) LMNAHTTRAB9ACCR1CCR5
SCHEMBL20515390 0.77 CCR1 (0.43) NPSR1PRNPLMNAHTTHPGD
SCHEMBL27512952 0.76 CCR1 (0.42) RAB9ACCR1CCR5MEN1KMT2A
SCHEMBL29923566 0.76 RAB9A (0.42) NPSR1RAB9ACCR1CCR5RXFP1
SCHEMBL4043717 0.74 CCR1 (0.41) HTTHPGDRAB9ACCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 US disclosed
EP-1244677-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-10-02 EP disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed
WO-2001046203-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA NPSR1 2978/4885PRNP 2788/4885LMNA 4443/4885
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO NPSR1 2167/4885PRNP 2012/4885LMNA 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.